ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12607000166471

Ethics application status

Approved

Date submitted

8/03/2007

Date registered

12/03/2007

Date last updated

30/04/2012

Type of registration

Prospectively registered

Titles & IDs

Public title

Effectiveness of Mindfulness-Based Cognitive Therapy Compared to Treatment-as-usual for Preventing Depressive Relapse in Subjects at Very High Risk

Scientific title

In people who have had at least three prior episodes of major depressive disorder is mindfulness based cognitive therapy more effective than treatment as usual in preventing relapse of major depression.

Secondary ID [1]

NHMRC Grant: 436897

Universal Trial Number (UTN)

Trial acronym

Depression Awareness Recovery Effectiveness (DARE)

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Major Depressive Disorder

Condition category

Condition code

Mental Health

Depression

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

This study is a randomised controlled trial, whereby participants will be randomised to mindfulness-based cognitive therapy (MBCT) or treatment as usual (TAU).

Mindfulness-based cognitive therapy (MBCT) is a manualised group based intervention designed to reduce rates of relapse of MDD. It integrates aspects of cognitive therapy with components of a mindfulness-based stress reduction program. It teaches clients to become more aware of, and to relate differently to, thoughts, feelings and bodily sensations; in particular, to view thoughts and feelings as passing events in the mind rather than as necessarily reflecting reality. The program teaches skills in disengagement from habitual (automatic) dysfunctional cognitive routines, especially depression-related ruminative thought patterns. Its efficacy in doing this has been demonstrated in two randomised controlled trials. It is now included in the UK Government’s National Institute of Clinical Excellence (NICE) Guidelines for prevention of depressive recurrence for patients who have suffered three or more episodes of depression. It has not been similarly recommended in other countries.

After an initial individual orientation session the MBCT program is delivered by an instructor in eight weekly 2 hour group training sessions involving up to 10 clients. Optional ‘booster sessions’ will be available on a 3-monthly basis following completion of the core program. Sessions incorporate mindfulness practices including meditation and also cognitive-behavioural therapy exercises. Homework for participants includes formal daily meditation practices and exercises for the development of mindful awareness within everyday activity. Emphasis later in the course is on combining cognitive-behaviour therapy (CBT) techniques such as conventional CBT activity scheduling with meditative practices into synergistic strategies for responding to negative mood states. Finally the course participants develop personal documentation detailing warning signs and related action plans, as well as considering how to maintain practices and habits they have found helpful.

Intervention code [1]

Prevention

Comparator / control treatment

The control condition will be treatment as usual. Participants will be encouraged to attend their regular treating practitioner(s) as they would if they were not involved in the trial. Also, both MBCT and treatment as usual groups are encouraged to use their regular research data monitoring of depressive symptoms as an aid to early recognition of relapse of MDD and to seek usual care if indicated in a process described as Depression Relapse Active Monitoring (DRAM). Antidepressant medication and other psychological interventions will be permitted in both arms of the trial if treating practitioners consider necessary. Such interventions will be monitored through collection of service contact information in both groups.

Control group

Active

Outcomes

Primary outcome [1]

Relapse of Major Depressive Disorder (MDD).

Timepoint [1]

Two year follow up following MBCT group, so approximately 26 months total for both groups. Status monitored with short questionnaire monthly, more extensive questionnaires three monthly and face to face interviews after 14 and 26 months.

Secondary outcome [1]

Time to relapse of MDD

Timepoint [1]

Monthly

Secondary outcome [2]

Time to clinical intervention for MDD

Timepoint [2]

Monthly

Secondary outcome [3]

Length of time spent in depressive episodes

Timepoint [3]

Based on monthly responses and also yeaarly interviews

Secondary outcome [4]

Anxiety symptoms

Timepoint [4]

Three monthly

Secondary outcome [5]

Quality of life

Timepoint [5]

Three monthly

Secondary outcome [6]

Social functioning

Timepoint [6]

Three monthly

Secondary outcome [7]

Health care costs

Timepoint [7]

Annual review

Secondary outcome [8]

Adherence to routinely prescribed antidepressant medication.

Timepoint [8]

Three monthly

Secondary outcome [9]

Rumination

Timepoint [9]

Three monthly

Secondary outcome [10]

Neuroticism

Timepoint [10]

Three monthly

Secondary outcome [11]

Open-ness to experience

Timepoint [11]

Three monthly

Eligibility

Key inclusion criteria

Ability to speak and read English fluently; and meeting DSM-IV criteria for three previous major depressive episodes.

Minimum age

18 Years

Maximum age

75 Years

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

A current episode of MDD; current symptoms of a psychotic disorder, or a past diagnosis of a psychotic disorder where the treating clinician believes the therapy may be contraindicated; current significant eating disorder or obsessive-compulsive disorder, organic mental disorder or pervasive developmental delay; current borderline or antisocial personality disorder; current alcohol or drug dependency other than tobacco; or current benzodiazepine intake of more than 20mg diazepam equivalent a day.

Study design

Purpose of the study

Prevention

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Enrolment will be through face to face interview with a researcher at which point informed consent will be invited. Allocation to treatment will be by a statistician in another centre.

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Stratified and using computer software, stratification according to gender, status in regards to prescribed medication and referral origin (Primary or Specialist services)

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

Intervention assignment

Parallel

Other design features

Assessors will as far as possible be blinded

Phase

Type of endpoint/s

Efficacy

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Date of first participant enrolment

Anticipated

1/05/2007

Actual

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

Sample size

Target

196

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

Funding & Sponsors

Funding source category [1]

Government body

Name [1]

National Health and Medical Research Council (Grant number: 436897)

Address [1]

National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601

Country [1]

Australia

Primary sponsor type

University

Name

Monash University

Address

Monash University, Clayton 3800

Country

Australia

Secondary sponsor category [1]

Hospital

Name [1]

Southern Health

Address [1]

Clayton Campus
246 Clayton Road, Clayton.
Victoria 3168

Country [1]

Australia

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Southern Health

Ethics committee address [1]

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

Approval date [1]

21/05/2007

Ethics approval number [1]

07056B

Ethics committee name [2]

Alfred Hospital Ethics Committee

Ethics committee address [2]

Ethics committee country [2]

Australia

Date submitted for ethics approval [2]

Approval date [2]

19/03/2008

Ethics approval number [2]

280/07

Ethics committee name [3]

Barwon Health

Ethics committee address [3]

Ethics committee country [3]

Australia

Date submitted for ethics approval [3]

Approval date [3]

21/02/2008

Ethics approval number [3]

07/86

Ethics committee name [4]

Peninsula Health

Ethics committee address [4]

Ethics committee country [4]

Australia

Date submitted for ethics approval [4]

Approval date [4]

16/01/2008

Ethics approval number [4]

2007/53

Ethics committee name [5]

Monash University Standing Committee on Ethics in Research involving Humans.

Ethics committee address [5]

Monash University, Vic 3800

Ethics committee country [5]

Australia

Date submitted for ethics approval [5]

Approval date [5]

03/07/2007

Ethics approval number [5]

CF07/1275-2007/0191MCC

Summary

Brief summary

More than one in twenty Australians experience depression in a single year and it is commonly a relapsing disorder.  At least 60% of people who have had a depressive episode will have another, the vast majority within two years of the index episode.  For those who have had three episodes, the relapse rate is 90%.  Even with guideline-based pharmacotherapy relapse is not uncommon so there is a need for non-pharmacological approaches to relapse prevention. The economic burden of depression in Australia has been estimated as perhaps 2.8 billion annually. Mindfulness-based cognitive therapy (MBCT) is an innovative psychological treatment, combining principles of cognitive therapy and mindfulness meditation.  It is designed to prevent relapse in people who have recovered from depressive episodes.  MBCT aims to teach people to become more aware of, and to related differently to, their thoughts, feelings and bodily sensations; in particular, to view these thoughts and feelings as passing events in the mind rather than identifying with them.  Through gaining these skills in increased awareness of thoughts and feelings, participants in the treatment learn to avoid negative ruminations, which have a powerful role in triggering relapses of depression.  This project will examine the effectiveness of MBCT for the first time in Australians with a history of recurring depression.  The primary aim of this project is to determine if MBCT when added to existing treatment as usual (TAU) is more effective than TAU in preventing depressive relapse over a two-year period in people who have had at least three prior episodes of depression.  The study also aims to establish whether the mechanisms by which MBCT is proposed to work – by decreasing rumination, increasing levels of mindfulness and self-awareness – do in fact operate.  We also hope to establish whether MBCT also has any impact on anxiety, another disabling condition that commonly occurs with depression.  Cost utility analysis will enable specific policy recommendations for Australia. Positive findings from this study would lead to MBCT having a high degree of evidence-based support examining its use, so that it could be considered as an intervention for which ‘high’, rather than ‘moderate’, levels of evidence exist. Hence, if outcomes are positive, this study would provide internationally significant findings to support consideration of inclusion of this treatment into guidelines for routine clinical management of the serious and disabling problem of recurrent depression.

Trial website

www.dare.org.au

Trial related presentations / publications

Publication. Shawyer, F., Meadows, G.N., Judd, F., Martin, P.R., Segal, Z., Piterman, L. (2012). The DARE study of relapse prevention in depression: design for a phase 1/2 translational randomised controlled trial involving mindfulness-based cognitive therapy and supported self monitoring. BMC Psychiatry, 12, 3.

Oral presentation. Shawyer, F., Meadows, G., Judd, F., Martin, P., Segal, Z., Piterman, L. Findings from the DARE study, a multisite study of MBCT with two year follow up, focusing on subgroups and time course. 10th Annual International Scientific Conference for Clinicians, Researchers and Educators: Investigating and Integrating Mindfulness in Medicine, Health Care and Society 28 March – 1 April 2012, Norwood, USA.

Poster presentation. Shawyer, F., Meadows, G., Judd, F., Martin, P., Segal, Z., Piterman, L. A randomised controlled trial of mindfulness-based cognitive therapy: study protocol and design highlighting phase 1 and phase 2 translational research elements. 10th Annual International Scientific Conference for Clinicians, Researchers and Educators: Investigating and Integrating Mindfulness in Medicine, Health Care and Society 28 March – 1 April 2012, Norwood, USA.

Oral presentation. Prowse, P., Meadows, G., Shawyer, F., Segal, Z. An exploratory study into the effectiveness of fidelity scales in the delivery of Mindfulness-Based Cognitive Therapy as part of the Depression Awareness Recovery Effectiveness (DARE) Program in Australia. 10th Annual International Scientific Conference for Clinicians, Researchers and Educators: Investigating and Integrating Mindfulness in Medicine, Health Care and Society 28 March – 1 April 2012, Norwood, USA.

Oral presentation. Meadows, G., Shawyer, F., Özmen, M., Judd, F., Martin, P., Segal, Z., Piterman, L. Introducing the DARE study, a multisite study of MBCT with two year follow up and including health economic evaluation. 10th Annual International Scientific Conference for Clinicians, Researchers and Educators: Investigating and Integrating Mindfulness in Medicine, Health Care and Society 28 March – 1 April 2012, Norwood, USA.

Oral presentation. Shawyer, F., Meadows, G., Judd, F., Piterman, L, Martin, P., Segal, Z., Piterman, L. Mindfulness-Based Cognitive Therapy for preventing relapse in recurrent depression: outcomes from the first year follow up of a randomised controlled trial. 34th Australian Association for Cognitive & Behaviour Therapy National Conference 26-30 October 2011, Sydney, Australia. 

Oral presentation. Shawyer, F., Meadows, G., Judd, F., Martin, P., Segal, Z., Piterman, L. Preliminary findings from a randomized controlled trial of Mindfulness-based cognitive therapy for recurrent depression. 27th International Congress of Applied Psychology, 11-16 July 2010, Melbourne, Australia. 

Poster presentation. Shawyer, F., Meadows, G., Judd, F., Martin, P., Segal, Z., Piterman, L. Does mindfulness-based cognitive therapy improve awareness and reduce rumination in recurrent depression and, if so, does antidepressant medication help? World Congress of Behavioral and Cognitive Therapies, June 2-5 2010, Boston, USA.

Poster presentation. Meadows, G., Shawyer, F., Graham, A. An exploratory effectiveness study with MBCT: findings and design issues. Investigating and Integrating Mindfulness in Medicine, Health Care and Society. 8th Annual International Scientific Conference. April 7-11 2010, Worcester, Massachusetts, USA.

Public notes

Contacts

Principal investigator

Name

Address

Country

Phone

Fax

Contact person for public queries

Name

Professor Graham Meadows

Address

Southern Synergy, Monash University Notting Hill Campus, c/- Wellington Rd Clayton, Victoria 3800

Country

Australia

Phone

613 99029696

Fax

613 9902 9900

Graham.Meadows@monash.edu

Contact person for scientific queries

Name

Professor Graham Meadows

Address

Southern Synergy, Monash University Notting Hill Campus, c/- Wellington Rd Clayton, Victoria 3800

Country

Australia

Phone

613 99029696

Fax

613 9902 9900

Graham.Meadows@monash.edu

No information has been provided regarding IPD availability

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

No additional documents have been identified.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically